| 1. | A few years passed , what is the performance of the companies which have invested the biopharmacy industry
几年过去了，这些投资生物制药的公司经营业绩到底如何 |
| 2. | Our country regards the biopharmacy industry as the emphasis and strategic target of the scientific technology development
我国已明确地将生物制药产业作为21世纪科技发展的重点和战略目标。 |
| 3. | However , some listing corporations do not achieve outstanding achievements . biopharmacy companies are faced with both huge developing potential and risks
生物制药上市公司企业面临着巨大的发展潜力，同时也承受着极大的风险。 |
| 4. | Chapter four is the emphasis of this dissertation , it focuses on the result of the performance evaluation of the biopharmacy public companies
第四章是本文的重点，主要介绍本文的实证结果，以及生物制药上市公司经营业绩评价结果。 |
| 5. | Since 1999 , many companies in our country started to go into the biopharmacy field by all kinds of forms , and invested the biopharmacy industry during the two years of 1997 - 1998
自1992年起，我国许多公司就开始以各种形式介入生物制药领域，并在1997 - 1998两年，形成了轰轰烈烈的投资生物制药的高潮。 |
| 6. | In this dissertation , i will select the excellent public companies which represent the biopharmacy industry as the study target , use the factor analysis method based on finance measures to evaluate the public companies of the biopharmacy industry
本文将把代表生物制药行业的优秀上市公司作为研究对象，采用以财务指标为基础的因子分析方法来综合评价生物制药上市公司的经营业绩。 |
| 7. | The topic of the first chapter is mainly to introduce the concept and the character of the biopharmacy , the development outline of the biopharmacy industry in our civil country and outside of our country and the public companies outline of the biopharmacy industry in our country
本文共分五章。第一章主要介绍生物制药的概念和特点、国内外生物制药行业发展概况以及我国生物制药上市公司概况。 |
| 8. | Acoording to company valuation theory , based on ananlysis and comparison of present company valuation model and valuation technology , combining characteristics of biopharmacy company of high technology , high risk , high profits , i take sichuan dikang science and technology pharmacy , a biomedical listing company for dcfm model value ' s valuation . through analysing dikang ' s past achievements and value - driving business , i made
本文根据公司价值的有关理论，对目前运用的公司价值评估模型和评估技术的进行分析和比较基础上，结合生物制药上市公司高技术、高风险、高收益等高新技术企业特点，选择贴现现金流模型对物制药上市公司? ?四川迪康科技药业股份有限公司的价值进行评估。 |
| 9. | Biopharmacy industry , as one of the four high technology industries in the 21 century , is rewarded as " the morning sun industry " and " the gold industry " for its great scientific research value , obvious economy yield , high growth speed and wide development perspective . government , high technology field and enterprise field all pay high attention to it and support it greatly
生物制药行业作为21世纪四大高科技产业之一，因其巨大的科研价值、显著的经济和社会效益、高速的成长性以及广阔的发展前景而被誉为“朝阳产业”和“黄金产业” ，各国政府、科技界和企业界都给予高度的重视和大力支持。 |
